论文信息 - Breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis are responsive to icatibant: findings from the Icatibant Outcome Survey - 字舞流文

Breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis are responsive to icatibant: findings from the Icatibant Outcome Survey

W. Aberer | B. Goichot | S. Kivity | M. Cicardi | K. Bork | E. Aygören‐Pürsün | M. Bova | A. Masseau | M. Maurer | H. Longhurst | M. Magerl | M. Maurer | T. Lobera | R. Cabañas | A. Sobel | G. Kanny | C. Bethune | A. Gompel | H. Longhurst | L. Bouillet | O. Fain | A. Reshef | A. Zanichelli | F. Arcoleo | Y. Graif | M. Baeza | M. Helbert | A. Bygum | L. Martin | V. Montinaro | I. Andresen | B. Coppéré | T. Caballero | H. Maillard | S. Guez | A. Perrin | R. Lleonart | Y. Ollivier | I. Martinez-Saguer | J. Arnolds | D. Launay | P. Manconi | A. Grumach | B. S. de San Pedro | C. H. de Larramendi | M. Wiednig | P. Jeandel | I. Boccon-Gibod | E. Toubi | M. Bauer | G. Marone | L. Marqués | Andrea Zanichelli | W M A A C I L B O B A S PY G D H L A Y A J E M M K M Aberer Wiednig Grumach Bygum Blanchard Delauny | C. Blanchard Delauny | M. Baş | E. Papadopoulou-Alataki | F. Psarros | A Zanichelli | M. Guilarte | D. Hernández | J. Bjoerkander | T. G. Pereira | Hilary J. Longhurst | T. Caballero | W. Aberer | M. Maurer

[1] E. Aygören‐Pürsün,et al. C1 Inhibitor for Routine Prophylaxis in Patients with Hereditary Angioedema: Interim Results from a European Registry Study , 2016 .

[2] W. Aberer,et al. The Icatibant Outcome Survey: treatment of laryngeal angioedema attacks , 2015, European journal of emergency medicine : official journal of the European Society for Emergency Medicine.

[3] G. Casazza,et al. Efficacy of on‐demand treatment in reducing morbidity in patients with hereditary angioedema due to C1 inhibitor deficiency , 2015, Allergy.

[4] M. Cicardi,et al. The safety of treatments for angioedema with hereditary C1 inhibitor deficiency , 2015, Expert opinion on drug safety.

[5] W. Aberer,et al. Analysis of characteristics associated with reinjection of icatibant: Results from the icatibant outcome survey. , 2015, Allergy and asthma proceedings.

[6] M. Gompels,et al. C1 inhibitor deficiency: 2014 United Kingdom consensus document , 2015, Clinical and experimental immunology.

[7] M. Triggiani,et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group , 2014, Allergy.

[8] M. Pedrosa,et al. Long-term prophylaxis with C1-inhibitor concentrate in patients with hereditary angioedema. , 2014, Journal of investigational allergology & clinical immunology.

[9] J. Sheikh,et al. A focused parameter update: hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor-associated angioedema. , 2013, The Journal of allergy and clinical immunology.

[10] W. Aberer,et al. Hereditary Angioedema Attacks Resolve Faster and Are Shorter after Early Icatibant Treatment , 2013, PloS one.

[11] K. Obtulowicz,et al. Recombinant human C1 inhibitor for the prophylaxis of hereditary angioedema attacks: a pilot study , 2013, Allergy.

[12] R. Lockey,et al. WAO Guideline for the Management of Hereditary Angioedema , 2012, The World Allergy Organization journal.

[13] B. Zuraw,et al. Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. , 2012, The American journal of medicine.

[14] M. Cicardi,et al. Hereditary angio-oedema , 2012, The Lancet.

[15] M. Triggiani,et al. Evidence‐based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group , 2012, Allergy.

[16] B. Chipps. Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema , 2011, Pediatrics.

[17] B. Zuraw. The Pathophysiology of Hereditary Angioedema , 2010, The World Allergy Organization journal.

[18] K. Bork,et al. Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[19] A. Sheffer,et al. Clinical and biochemical effects of stanozolol therapy for hereditary angioedema. , 1981, The Journal of allergy and clinical immunology.

[20] P. Naish,et al. Hereditary angiooedema. , 1979, Lancet.

[21] D. Alling,et al. Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. , 1976, The New England journal of medicine.

[22] D. Alling,et al. Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. , 1976, The New England journal of medicine.